Triple-Frequency Electromagnetic Stimulation Combined with Fingolimod Reduces Breast Cancer Cell Proliferation and Metastasis-Associated Extracellular Vesicle Protein Levels
Greg Haroutunian, Lawrence Daniels, Ashot Tsaghikian, Caifeng Zhao, Phaedon Zavras, Svetlana Marukian, Haiyan Zheng, Arevik Mosoian · 2026
Read Triple-Frequency Electromagnetic Stimulation Combined with Fingolimod Reduces Breast Cancer Cell Proliferation and Metastasis-Associated Extracellular Vesicle Protein Levels by Greg Haroutunian, Lawrence Daniels, Ashot Tsaghikian, Caifeng Zhao, Phaedon Zavras, Svetlana Marukian, Haiyan Zheng, Arevik Mosoian (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13610236.txt.
Description
Greg Haroutunian and co-authors combine a three-frequency electromagnetic device with an immune drug against triple-negative breast cancer cells. Their 2026 study targets a cancer type that resists many therapies and spreads aggressively. Tumor cells also shed tiny vesicles whose protein cargo helps spread. Standard field therapy uses high-frequency fields to jam cell division; this low-energy, three-frequency variant was barely characterized.
Two breast cancer cell lines received the field treatment, the drug fingolimod, both together, or a standard chemotherapy as control. The field alone slowed growth in both lines and reshaped the cells as if their division cycle had shifted. Protein profiling of shed vesicles then measured how each treatment changed the spread-linked cargo the cells export.
Catalog record
| CREATOR | Greg Haroutunian, Lawrence Daniels, Ashot Tsaghikian, Caifeng Zhao, Phaedon Zavras, Svetlana Marukian, Haiyan Zheng, Arevik Mosoian |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 70 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |